RPRX Key Stats
- FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Sever... May 22
- REPROS THERAPEUTICS INC. Financials May 17
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure May 16
- Repros Therapeutics, Inc. (RPRX) Posts Q1 Loss of 41c/Share Street Insider May 10
- Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results GlobeNewswire May 10
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin May 10
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial... May 10
- Repros Patent Problems Began When Harry Met Joe May 9
- Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule GlobeNewswire May 2
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events May 2
RPRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Repros Therapeutics is up 104.0% over the last year vs S&P 500 Total Return up 28.40%, Biosante Pharmaceuticals down 58.79%, and Auxilium Pharmaceuticals down 19.60%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for RPRX
Pro Report PDF for RPRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download RPRX Pro Report PDF
Pro Strategies Featuring RPRX
Did Repros Therapeutics make it into our Pro Portfolio Strategies?
Repros Therapeutics Inc., is a US-based development stage biopharmaceutical company headquartered in The Woodlands, Texas. Founded in 1987 as Zonagen, it is focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski is the CEO of this company.